ACCESS RECORDING

Blood biomarkers are transforming research and clinical care for dementia, Alzheimer’s, and other neurodegenerative diseases. In this webinar, we’ll explore their evolution, from global proteomics to disease-specific markers such as p-tau, GFAP, and amyloid-beta. The session will focus on the utility of plasma p-tau217, and will look to future possibilities — including remote testing and emerging markers — to further highlight biomarkers’ role in improving dementia diagnosis and treatment.

Speaker

Nicholas Ashton, Ph.D. 
Associate Professor, University of Gothenburg

After receiving his Ph.D. from King’s College, Dr. Ashton joined the University of Gothenburg, where he has made major contributions to the development and use of biofluid assays for Alzheimer’s disease and related disorders. One of the most highly-cited researchers, he has published more than 200 articles and, in 2021, received the Queen Silvia Prize for a Young Alzheimer’s Researcher.

ACCESS RECORDING